CONTEXT THERAPEUTICS INC
CNTXNASDAQ🏆 #4602 by market capEarnings Nov 11US Equity
$0.21▼ $0.02 (−10.19%)
Pre-market · at closeTrack CNTX
Get earnings, price moves & breaking news on Telegram
24h▼ 10.2%
7d▼ 8.1%
14d▼ 11.4%
30d▼ 33.3%
ytd▼ 85.5%
1y▼ 81.5%
🏦Market Cap
$20M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $0.21 – $0.23
- 52-Week Range
- $0.22 – $3.62
- Volume (shares)
- 36,132
- Avg Volume (shares)
- —
- Shares Outstanding
- 91.9M
- Next Earnings
- 2026-11-11
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.48
- Dividend Yield
- —
- Dilution (1yr)
- +57.3%
CONTEXT THERAPEUTICS INC
CNTXFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$40M▲ +32.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$26M▼ −9.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
91.9M▲ +57.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$66M▼ −$28M YoY
StockOtter · stockotter.spaceAbout CONTEXT THERAPEUTICS INC
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
16 analysts
Strong Buy4
Buy11
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.